Abstract:Significance Two of the most debilitating and scientifically challenging diseases of the 21st century are cancer and neurodegeneration. Although cancer results from excessive cell growth, neurodegeneration is a consequence of excessive cell loss. Dysfunction of the same key regulators, including oncogenes and tumor suppressors, may cause both diseases. We report that LPS and IFN induce apoptosis-stimulating protein of p53 with signature sequences of ankyrin repeat-, SH3 domain-, and proline-rich region-containing protein 2 (ASPP2) transcription through a signal transducer and activator of transcription 1 (STAT1) -dependent but NF-κB RELA/p65-independent pathway and that ASPP2 mediates LPS-induced apoptosis. Thus, the identified STAT1/ASPP2 pathway reveals an important function of ASPP2 in the cellular response to inflammation and infection and connects neuroinflammation to cell polarity and tumor suppression. Inflammation and loss of cell polarity play pivotal roles in neurodegeneration and cancer. A central question in both diseases is how the loss of cell polarity is sensed by cell death machinery. Here, we identify apoptosis-stimulating protein of p53 with signature sequences of ankyrin repeat-, SH3 domain-, and proline-rich region-containing protein 2 (ASPP2), a haploinsufficient tumor suppressor, activator of p53, and regulator of cell polarity, as a transcriptional target of signal transducer and activator of transcription 1 (STAT1). LPS induces ASPP2 expression in murine macrophage and microglial cell lines, a human monocyte cell line, and primary human astrocytes in vitro. LPS and IFNs induce ASPP2 transcription through an NF-κB RELA/p65-independent but STAT1-dependent pathway. In an LPS-induced maternal inflammation mouse model, LPS induces nuclear ASPP2 in vivo at the blood–cerebral spinal fluid barrier (the brain’s barrier to inflammation), and ASPP2 mediates LPS-induced apoptosis. Consistent with the role of ASPP2 as a gatekeeper to inflammation, ASPP2-deficient brains possess enhanced neuroinflammation. Elevated ASPP2 expression is also observed in mouse models and human neuroinflammatory disease tissue, where ASPP2 was detected in GFAP-expressing reactive astrocytes that coexpress STAT1. Because the ability of ASPP2 to maintain cellular polarity is vital to CNS development, our findings suggest that the identified STAT1/ASPP2 pathway may connect tumor suppression and cell polarity to neuroinflammation.

Mutant Ras and Inflammation-Driven Skin Tumorigenesis is Suppressed Via a JNK-iASPP-AP1 Axis

The Tumor Suppressor Gene, RASSF1A, is Essential for Protection Against Inflammation -Induced Injury

PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway.

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

Mutant Nrf2E79Q enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors

An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice

Mutant Kras Co-Opts a Proto-Oncogenic Enhancer Network in Inflammation-Induced Metaplastic Progenitor Cells to Initiate Pancreatic Cancer

Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer

Injury prevents Ras mutant cell expansion in mosaic skin

Mutually Exclusive Mutations Of The Pten And Ras Pathways In Skin Tumor Progression

PRAK Is Essential for ras-Induced Senescence and Tumor Suppression

Mutant P53r270h Drives Altered Metabolism and Increased Invasion in Pancreatic Ductal Adenocarcinoma.

iASPP Is an Antioxidative Factor and Drives Cancer Growth and Drug Resistance by Competing with Nrf2 for Keap1 Binding

Mutant p53 leads to low-grade IFN-I-induced inflammation and impairs cGAS-STING signalling in mice

Inactivation of a Gα(s)-PKA tumour suppressor pathway in skin stem cells initiates basal-cell carcinogenesis

Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors

STAT1-induced ASPP2 Transcription Identifies a Link Between Neuroinflammation, Cell Polarity, and Tumor Suppression

REGγ is Critical for Skin Carcinogenesis by Modulating the Wnt/β-catenin Pathway

Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within Interleukin-6 family cytokines

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

Nuclear Iaspp Determines Cell Fate by Selectively Inhibiting Either P53 or NF-κB